Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2887544 | 0.92 | HRH3 (0.54) | HPGDHRH3SMN1; SMN2PKML3MBTL3 | |
| SCHEMBL2879601 | 0.92 | HRH3 (0.54) | HPGDHRH3SMN1; SMN2PKML3MBTL3 | |
| SCHEMBL2885504 | 0.92 | HRH3 (0.54) | HPGDHRH3SMN1; SMN2PKML3MBTL3 | |
| SCHEMBL2878841 | 0.86 | HRH3 (0.57) | HRH3L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL2886402 | 0.86 | HRH3 (0.57) | HRH3L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL2879242 | 0.84 | KDM1A (0.45) | HPGDHRH3SMN1; SMN2PKMMEN1 | |
| SCHEMBL2883891 | 0.84 | KDM1A (0.45) | HPGDHRH3SMN1; SMN2PKMMEN1 | |
| SCHEMBL4765310 | 0.79 | HRH3 (0.70) | HRH3L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL2881648 | 0.79 | HRH3 (0.70) | HRH3L3MBTL3L3MBTL1MEN1KMT2A | |
| SCHEMBL2886245 | 0.79 | HRH3 (0.70) | HRH3L3MBTL3L3MBTL1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | WYETH (US) | 2007-09-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219240-A1 | N-substituted-azacyclylamines as histamine-3 antagonists | HNMT, HRH4, HRH3 | HPGD 508/4885HRH3 3/4885SMN1; SMN2 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.